Exploring the effects of sleep loss on aging and cognitive decline
The Peripheral Blood Multi-Omics Study on the Association of Sleep Loss With Aging and Alzheimer's Disease
This study is testing how not getting enough sleep affects thinking and aging in healthy people and those with memory problems or Alzheimer's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | First Affiliated Hospital of Zhejiang University Academic / other |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06492109 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of sleep deprivation on cognitive function and aging by analyzing blood samples from participants of varying ages and cognitive levels. It includes healthy individuals, those with mild cognitive impairment (MCI), and Alzheimer's disease (AD) patients. Participants will undergo cognitive assessments and sleep screenings, with blood samples collected before and after sleep deprivation for multi-omics analysis. The goal is to identify molecular biomarkers that link sleep loss with aging and neurodegenerative diseases.
Who should consider this trial
Good fit: Ideal candidates include healthy individuals, patients with mild cognitive impairment, and those diagnosed with Alzheimer's disease.
Not a fit: Patients with severe psychiatric conditions or significant medical issues that could interfere with study participation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights into the biological mechanisms of sleep loss and its effects on cognitive decline, potentially informing treatment strategies for neurodegenerative diseases.
How similar studies have performed: While there is ongoing research into sleep and cognitive function, this study's multi-omics approach to understanding the relationship between sleep loss and aging is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signed informed consent form； 2. Meet the inclusion criteria for each arms. Exclusion Criteria: 1. Failure to provide informed consent; 2. Inability to follow study procedures due to issues such as language barriers or cognitive impairment; 3. Regular use of medications that may alter the relationship between sleep and outcome variables (e.g., opioid medications, benzodiazepines, and Z drugs \[non-benzodiazepine hypnotics\]); 4. History of alcohol abuse, substance abuse, consciousness disorders, cerebrovascular disease, head injury, epilepsy, encephalitis, or other neurological disorders; 5. Diagnosis of schizophrenia, severe depression, anxiety disorders, or other severe psychiatric conditions; 6. Presence of severe arrhythmias, myocardial infarction within the last 6 months, severe pulmonary dysfunction, renal or hepatic insufficiency, severe anemia, severe gastrointestinal diseases, tumors, or other severe medical conditions.
Where this trial is running
Hangzhou, Zhejiang
- The First Affiliated Hospital of Zhejiang University — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Benyan Luo — Zhejiang University
- Study coordinator: Benyan Luo, Prof
- Email: luobenyan@zju.edu.cn
- Phone: 0571-87236537
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.